Botanix Pharmaceuticals

Australian Cannabis Index | New York and New Jersey Face Potential Pot Shortage

Cannabis producers are now well-positioned to capitalize on this supply shortfall, which is only expected to worsen once the Big Apple's nascent recreational market begins to build...

Australian Cannabis Index | Credit Suisse Group Ceases Pot Stock Transactions

The fallout of this decision can already be seen in the performance of the AdvisorShares Pure US Cannabis ETF, which has seen its share price dive by more than 20% since February 2...

Australian Cannabis Index | HMMJ Rebalances as Creso Targets Psychedelics

The index remains bullish on the US market, as a number of regulatory reforms are expected to supercharge the cannabis industry during 2021.After dipping at the start of last week ...

The Oceania Cannabis Industry Could Be Worth $1.55B by 2024 – Prohibition Partners Report

A new report from Prohibition Partners has been released detailing the state of play for the burgeoning cannabis industry in the region of Oceania. Read this article for more infor...

Botanix Pharma Talks With FDA on Antibacterial Drug

Botanix Pharma (ASX:BOT) may soon be able to initiate clinical development of its cannabinoid-derived antimicrobial formula BTX 1801 in the United States, following a positive disc...

Mark Bernberg Sits Down With Stockhead to Discuss the Cannabis Industry

For ASX-listed cannabis stocks, the 2019 bear market claimed more than a few scalps. The Green Fund's CEO Mark Bernberg sat down with Stockhead to give a prognosis on the industry ...

Botanix Gets Grant To Study Synthetic CBD

Botanix Pharma (ASX: BOT) has been awarded a $50,000 Innovation Connections Grant by the Australian Government's Department of AusIndustry to research synthetic cannabidiol.Botanix...

Botanix Announces CBD Supply Agreement With Purisys

Following the news that Botanix Pharma (ASX: BOT) will be receiving $50,000 from the Australian government to research synthetic CBD, the company has now secured a cannabidiol supp...

Botanix Pharma Launches Rosacea Study

Botanix Pharma moves ahead on trialing its unique cannabinoid formulation BTX 1702 for papulopustular rosacea. Botanix Pharmaceuticals Limited has announced that it has received et...

Guess Who's Back? Matt Callahan Rejoins Botanix

Matt Callahan will be re-joining the Botanix Board as an Executive Director, while Rob Towner will step down from his role as Non-Executive Director. Following his temporary leave ...